ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Apr 21, 2022||ENDRA Life Sciences Raises $8.7 Million in Gross Proceeds Through its At-The-Market Facility|
|Feb 11, 2022||ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Portfolio with Issuance of 6th and 7th European Patents|
|Feb 09, 2022||ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS® System|
|Jan 24, 2022||ENDRA Life Sciences Expands into China with Shanghai General Hospital Partnership|
|Jan 05, 2022||ENDRA Life Sciences to Present at the H.C. Wainwright BioConnect Virtual Conference|